Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy
NCT ID: NCT00256698
Last Updated: 2012-08-01
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
514 participants
INTERVENTIONAL
2004-01-31
2012-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Anastrozole
Anastrozole
1 mg oral tablet
2
Anastrozole + Fulvestrant
Fulvestrant
intramuscular injection 250 mg loading dose (LD) regimen
Anastrozole
1 mg oral tablet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fulvestrant
intramuscular injection 250 mg loading dose (LD) regimen
Anastrozole
1 mg oral tablet
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Premenopausal women
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Roger Henriksson, MD
Role: STUDY_DIRECTOR
AstraZeneca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Brampton, , Canada
Research Site
Halifax, , Canada
Research Site
Kingston, , Canada
Research Site
Ontario, , Canada
Research Site
Toronto, , Canada
Research Site
San José, , Costa Rica
Research Site
Hämeenlinna, , Finland
Research Site
Turku, , Finland
Research Site
Avignon, , France
Research Site
Caen, , France
Research Site
Créteil, , France
Research Site
Grenoble, , France
Research Site
La Chaussée-Saint-Victor, , France
Research Site
Perpignan, , France
Research Site
Périgueux, , France
Research Site
Saint Cyr Sur Louire, , France
Research Site
Toulouse, , France
Research Site
Augsburg, , Germany
Research Site
Cologne, , Germany
Research Site
Düsseldorf, , Germany
Research Site
Erlangen, , Germany
Research Site
Frankfurt, , Germany
Research Site
Gifhorn, , Germany
Research Site
Großhadern, , Germany
Research Site
Halle, , Germany
Research Site
Hamburg, , Germany
Research Site
Hanover, , Germany
Research Site
Heidelberg, , Germany
Research Site
Ingolstadt, , Germany
Research Site
Kassel, , Germany
Research Site
Kiel, , Germany
Research Site
Leipzig, , Germany
Research Site
Leverkusen, , Germany
Research Site
Magdeburg, , Germany
Research Site
Mannheim, , Germany
Research Site
Marburg, , Germany
Research Site
München, , Germany
Research Site
Rostock, , Germany
Research Site
Trier, , Germany
Research Site
Ulm, , Germany
Research Site
Ziwicken, , Germany
Research Site
Guatemala City, , Guatemala
Research Site
Reykjavik, , Iceland
Research Site
Como, , Italy
Research Site
Fabriano, , Italy
Research Site
Ferrara, , Italy
Research Site
Florence, , Italy
Research Site
Lugo, , Italy
Research Site
Milan, , Italy
Research Site
Taormina, , Italy
Research Site
Treviglio, , Italy
Research Site
Vicenza, , Italy
Research Site
Drammen, , Norway
Research Site
Ilesund, , Norway
Research Site
Oslo, , Norway
Research Site
Porsgrunn, , Norway
Research Site
Stavanger, , Norway
Research Site
Troms, , Norway
Research Site
Trondheim, , Norway
Research Site
Cascais, , Portugal
Research Site
Coimbra, , Portugal
Research Site
Lisbon, , Portugal
Research Site
Santa Maria da Feira, , Portugal
Research Site
Halmstad, , Sweden
Research Site
Helsingborg, , Sweden
Research Site
Kalmar, , Sweden
Research Site
Karlskrona, , Sweden
Research Site
Kristianstad, , Sweden
Research Site
Link'ping, , Sweden
Research Site
M'lndal, , Sweden
Research Site
Malm, , Sweden
Research Site
Norrk'ping, , Sweden
Research Site
Skellefteå, , Sweden
Research Site
Skövde, , Sweden
Research Site
Södra Sunderbyn, , Sweden
Research Site
Stockholm, , Sweden
Research Site
Sundsvall, , Sweden
Research Site
Umeå, , Sweden
Research Site
V'rnamo, , Sweden
Research Site
V'stervik, , Sweden
Research Site
Varberg, , Sweden
Research Site
Ankara, , Turkey (Türkiye)
Research Site
Edirne, , Turkey (Türkiye)
Research Site
Gaziantep, , Turkey (Türkiye)
Research Site
Istanbul, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
9238SW/0001
Identifier Type: -
Identifier Source: secondary_id
FACT
Identifier Type: -
Identifier Source: secondary_id
D6997L00002
Identifier Type: -
Identifier Source: org_study_id